The obesity drug landscape
CagriSema did not arrive in a vacuum. It competes in the most active area of drug development in a generation, against…
Where CagriSema sits in a crowded field
CagriSema did not arrive in a vacuum. It competes in the most active area of drug development in a generation, against approved heavyweights (semaglutide, tirzepatide) and other investigational multi-hormone drugs (retatrutide, survodutide, eloralintide).
This unit places CagriSema honestly on that map: competitive on weight loss, distinctive in mechanism, but behind on the cardiovascular, liver, and durability evidence its rivals have accumulated.
Key terms
Weight loss, side by side
The first question everyone asks is "how much weight?" Placed against its rivals, CagriSema is competitive but not dominant: it lands in the same broad 20-25% band as tirzepatide and retatrutide, well above semaglutide alone, but it does not lead. The one direct comparison run so far, REDEFINE 4, put it slightly behind tirzepatide.
A crucial caveat sits under this chart: most of these numbers come from different trials, timepoints, and populations, so the bars are suggestive, not a fair head-to-head. The exception is tirzepatide. In REDEFINE 4 (open-label phase 3, n=809, 84 weeks) CagriSema lost 23.0% against tirzepatide 15 mg at 25.5% under the if-all-adhere estimand, and 20.2% against 23.6% under the treatment-regimen estimand, missing its non-inferiority target. Those figures come from the sponsor headline announcement of 23 February 2026, not yet a peer-reviewed paper, and the registry carries no posted results. Retatrutide has still not been compared with CagriSema directly. The honest read is that CagriSema is firmly in the top tier of weight-loss efficacy, and that claims it is "the strongest" now run against a direct trial result.
Except for tirzepatide, these bars are from separate trials, not head-to-heads. Where a direct comparison does exist, REDEFINE 4, CagriSema came in below tirzepatide rather than above it.